Health Canada RSS - MedEffect Canada - Canadian Adverse Reaction Newsletterhttp://www.hc-sc.gc.ca/rss/dhp-mps/carn-bcei-eng.xmlHealth Canadahttp://www.hc-sc.gc.ca2013-06-24T09:40:32-05:00http://www.hc-sc.gc.ca/images/templates/wmms.gifhttp://www.hc-sc.gc.ca/images/common/sm-rss.gifReceive alerts when the quarterly Canadian Adverse Reaction Newsletter (CARN) is published. The Bulletin contains articles for health professionals about specific health products, reported side effects and annual adverse reaction statistics.The material on this website is covered by the provisions of the Copyright Act, by Canadian laws, policies, regulations and international agreements. Such provisions serve to identify the information source and, in specific instances, to prohibit reproduction of materials without copyright clearance.Summary Safety Review - DICLECTIN (doxylamine and pyridoxine combination) - Assessing Safety in Pregnancyhttp://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/diclectin-eng.phpHealth Canadahttp://www.hc-sc.gc.ca2016-07-19T13:00:30-05:002016-07-19T13:00:30-05:00A summary safety review for Diclectin and the possible risk of safety in pregnancy is now available.The material on this website is covered by the provisions of the Copyright Act, by Canadian laws, policies, regulations and international agreements. Such provisions serve to identify the information source and, in specific instances, to prohibit reproduction of materials without copyright clearance.Summary Safety Review - Avonex (interferon beta-1a) - Assessing the Potential Risk of kidney Damage (nephrotic syndrome)http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/avonex2-eng.phpHealth Canadahttp://www.hc-sc.gc.ca2016-06-30T16:00:00-05:002016-06-30T16:00:00-05:00A summary safety review for Avonex (interferon beta-1a) and the possible risk of Kidney damage (nephrotic syndrome) is now available.The material on this web site is covered by the provisions of the Copyright Act, by Canadian laws, policies, regulations and international agreements. Such provisions serve to identify the information source and, in specific instances, to prohibit reproduction of materials without copyright clearance.Summary Safety Review - PERJETA (pertuzumab) - Assessing the Potential Risk of Stevens-Johnson Syndromehttp://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/perjeta-eng.phpHealth Canadahttp://www.hc-sc.gc.ca2016-04-04T11:20:00-05:002016-04-04T11:20:00-05:00A summary safety review for Perjeta (pertuzumab) and the potential risk of Stevens-Johnson Syndrome (serious condition of the skin and mucous membranes) is now available.The material on this web site is covered by the provisions of the Copyright Act, by Canadian laws, policies, regulations and international agreements. Such provisions serve to identify the information source and, in specific instances, to prohibit reproduction of materials without copyright clearance.Monthly Update to the List of New Safety Reviewshttp://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/new-nouveaux-eng.phpHealth Canadahttp://www.hc-sc.gc.ca2015-11-23T11:25:00-04:002015-11-23T11:25:00-04:00The list of new safety reviews has been updated and now includes safety reviews initiated between October 1 and October 31, 2015. The next update Is Schedule for December, 2015.The material on this website is covered by the provisions of the Copyright Act, by Canadian laws, policies, regulations and international agreements. Such provisions serve to identify the information source and, in specific instances, to prohibit reproduction of materials without copyright clearance.Summary Safety Review - Strontium - Risk of Heart and Circulatory Side Effectshttp://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/strontium-eng.phpHealth Canadahttp://www.hc-sc.gc.ca2015-10-22T11:45:00-04:002015-10-22T11:45:00-04:00A summary safety review for Strontium and the potential risk of serious heart and circulatory side effects is now available.The material on this website is covered by the provisions of the Copyright Act, by Canadian laws, policies, regulations and international agreements. Such provisions serve to identify the information source and, in specific instances, to prohibit reproduction of materials without copyright clearance.Quarterly Update to the List of New Safety Reviewshttp://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/new-nouveaux-eng.phpHealth Canadahttp://www.hc-sc.gc.ca2015-10-14T14:00:00-04:002015-10-14T14:00:00-04:00The list of new safety reviews has been updated and now includes safety reviews initiated between July 1 and September 30, 2015. The next update is scheduled for January, 2016.The material on this website is covered by the provisions of the Copyright Act, by Canadian laws, policies, regulations and international agreements. Such provisions serve to identify the information source and, in specific instances, to prohibit reproduction of materials without copyright clearance.Summary Safety Review - REVOLADE (eltrombopag) - Serious Skin Reactionshttp://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/revolade-eng.phpHealth Canadahttp://www.hc-sc.gc.ca2015-09-10T14:00:00-04:002015-09-10T14:00:00-04:00A summary safety review for Revolade (eltrombopag) and the potential link with serious skin reactions is now available.The material on this website is covered by the provisions of the Copyright Act, by Canadian laws, policies, regulations and international agreements. Such provisions serve to identify the information source and, in specific instances, to prohibit reproduction of materials without copyright clearance.Health Canada launched the Health Product InfoWatchhttp://www.hc-sc.gc.ca/dhp-mps/medeff/subscribe-abonnement/rss-eng.php Health Canada http://www.hc-sc.gc.ca2015-01-29T15:45:00-05:002015-01-29T15:45:00-05:00The Canadian Adverse Reaction Newsletter (CARN) is taking on a new format and name. On January 29, 2015, Health Canada launched the Health Product InfoWatch, a monthly publication that includes a recap of health product advisories and summary safety reviews published in the previous month, as well as new health product safety information. The CARN RSS Feed is being discontinued and will be updated with the new Health Product InfoWatch RSS Feed.The material on this web site is covered by the provisions of the Copyright Act, by Canadian laws, policies, regulations and international agreements. Such provisions serve to identify the information source and, in specific instances, to prohibit reproduction of materials without copyright clearance.Canadian Adverse Reaction Newsletter, Volume 24 - Issue 4 - October 2014 http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v24n4-eng.php Health Canada http://www.hc-sc.gc.ca2014-10-30T13:30:00-05:002014-10-30T13:30:00-05:00In this issue: Incretin-based therapies and the risk of pancreatic cancer; Intravenous methylprednisolone and liver injury; Sorafenib and osteonecrosis of the jaw; Summary of advisoriesThe material on this web site is covered by the provisions of the Copyright Act, by Canadian laws, policies, regulations and international agreements. Such provisions serve to identify the information source and, in specific instances, to prohibit reproduction of materials without copyright clearance.Canadian Adverse Reaction Newsletter, Volume 24 - Issue 3 – July 2014http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v24n3-eng.phpHealth Canadahttp://www.hc-sc.gc.ca2014-07-31T13:15:00-05:002014-07-31T13:15:00-05:00In this issue: Cisplatin and aortic thrombosis; Hydroxychloroquine and hypoglycemia; Case presentation: Suspected interaction between ginkgo biloba and efavirenz; Summary of advisories.The material on this website is covered by the provisions of the Copyright Act, by Canadian laws, policies, regulations and international agreements. Such provisions serve to identify the information source and, in specific instances, to prohibit reproduction of materials without copyright clearance.Canadian Adverse Reaction Newsletter, Volume 24 - Issue 2 – April 2014http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v24n2-eng.phpHealth Canadahttp://www.hc-sc.gc.ca2014-05-06T11:35:00-05:002014-05-06T11:35:00-05:00In this issue: Quetiapine and acute liver failure; Azithromycin and drug reaction with eosinophilia and systemic symptoms; Clopidogrel and acquired hemophilia; Summary of advisories.The material on this website is covered by the provisions of the Copyright Act, by Canadian laws, policies, regulations and international agreements. Such provisions serve to identify the information source and, in specific instances, to prohibit reproduction of materials without copyright clearance.Canadian Adverse Reaction Newsletter, Volume 24 - Issue 1 – January 2014http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v24n1-eng.phpHealth Canadahttp://www.hc-sc.gc.ca2014-02-14T08:40:00-05:002014-02-14T08:40:00-05:00In this issue: Vascular endothelial growth factor receptor inhibitors and thrombotic microangiopathy; Incidents involving the combined use of Durepair Dura Regeneration Matrix with ancillary wound closure products; Summary of advisoriesThe material on this website is covered by the provisions of the Copyright Act, by Canadian laws, policies, regulations and international agreements. Such provisions serve to identify the information source and, in specific instances, to prohibit reproduction of materials without copyright clearance.Canadian Adverse Reaction Newsletter, Volume 23 - Issue 4 - October 2013http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v23n4-eng.phpHealth Canadahttp://www.hc-sc.gc.ca2013-10-08T10:00:00-05:002013-10-08T10:00:00-05:00In this Issue: Adverse reaction reports make a difference; Summary of advisories.The material on this website is covered by the provisions of the Copyright Act, by Canadian laws, policies, regulations and international agreements. Such provisions serve to identify the information source and, in specific instances, to prohibit reproduction of materials without copyright clearance.Canadian Adverse Reaction Newsletter, Volume 23 - Issue 2 - April 2013http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v23n2-eng.phpHealth Canadahttp://www.hc-sc.gc.ca2013-06-25T10:00:00-05:002013-04-16T12:25:00-05:00In this issue: Intraocular lenses and the development of glistenings; Exenatide: international reports of pancreatic cancer; Summary of advisoriesThe material on this website is covered by the provisions of the Copyright Act, by Canadian laws, policies, regulations and international agreements. Such provisions serve to identify the information source and, in specific instances, to prohibit reproduction of materials without copyright clearance.Canadian Adverse Reaction Newsletter, Volume 23 - Issue 1 - January 2013http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v23n1-eng.phpHealth Canadahttp://www.hc-sc.gc.ca2013-01-08T10:45:00-05:002013-01-08T10:45:00-05:00In this issue: Pico-Salax (sodium picosulfate/magnesium citrate) and convulsions; Risperidone and rhabdomyolysis independent of neuroleptic malignant syndrome; Docetaxel and serious respiratory-related adverse reactions; Case presentation: Ear drops containing peanut oil and suspected association with anaphylaxis; Summary of advisoriesThe material on this website is covered by the provisions of the Copyright Act, by Canadian laws, policies, regulations and international agreements. Such provisions serve to identify the information source and, in specific instances, to prohibit reproduction of materials without copyright clearance.